These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29266398)

  • 1. Randomized open-label crossover assessment of Prograf vs Advagraf on immunosuppressant pharmacokinetics and pharmacodynamics in simultaneous pancreas-kidney patients.
    Cattral M; Luke S; Knauer MJ; Norgate A; Schiff J; Muirhead N; Luke PP
    Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29266398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels.
    Crespo M; Mir M; Marin M; Hurtado S; Estadella C; Gurí X; Rap O; Moral R; Puig JM; Lloveras J
    Transplant Proc; 2009; 41(6):2115-7. PubMed ID: 19715848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advagraf® with or without an induction therapy for de novo kidney-transplant recipients.
    Noble J; Jouve T; Rostaing L; Malvezzi P
    Expert Rev Clin Immunol; 2018 Jun; 14(6):461-467. PubMed ID: 29757021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prograf produces more benefits for CYP3A5 low expression patients in early stage after kidney transplantation.
    Fan B; Qiu K; Jiang Y; Hu X; Yin H; Wang W; Ren L; Liu H; Wang W; Zhang X
    Biomed Pharmacother; 2017 Apr; 88():738-744. PubMed ID: 28157649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion from Prograf to Advagraf in stable kidney transplant recipients: better renal function after 3-year follow-up.
    Spagnoletti G; Gargiulo A; Salerno MP; Favi E; Pedroso JA; Calia R; Romagnoli J; Citterio F
    Transplant Proc; 2014 Sep; 46(7):2224-7. PubMed ID: 25242756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from Prograf to Advagraf in adolescents with stable liver transplants: comparative pharmacokinetics and 1-year follow-up.
    Carcas-Sansuán AJ; Hierro L; Almeida-Paulo GN; Frauca E; Tong HY; Díaz C; Piñana E; Frías-Iniesta J; Jara P
    Liver Transpl; 2013 Oct; 19(10):1151-8. PubMed ID: 23894093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant reduction of Tacrolimus trough level after conversion from twice daily Prograf to once daily Advagraf in Chinese renal transplant recipients with or without concomitant diltiazem treatment.
    Ma MK; Kwan LP; Mok MM; Yap DY; Tang CS; Chan TM
    Ren Fail; 2013 Aug; 35(7):942-5. PubMed ID: 23815459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of conversion from Advagraf to twice-daily generic tacrolimus in kidney transplant recipients: a single-center study.
    Melo MJ; Gonçalves J; Guerra JO; Santana A; Nascimento C
    Transplant Proc; 2015 May; 47(4):911-3. PubMed ID: 26036484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switch from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in kidney transplantation.
    Iaria G; Sforza D; Angelico R; Toti L; de Luca L; Manuelli M; Bellini I; Manzia TM; Anselmo A; Tisone G
    Transplant Proc; 2011 May; 43(4):1028-9. PubMed ID: 21620043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion from Twice-Daily Prograf
    Yau WP; Loh CW; Vathsala A
    Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):481-492. PubMed ID: 30471066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients.
    Wu MJ; Cheng CY; Chen CH; Wu WP; Cheng CH; Yu DM; Chuang YW; Shu KH
    Transplantation; 2011 Sep; 92(6):648-52. PubMed ID: 21912349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from Prograf to Advagraf in stable paediatric renal transplant patients and 1-year follow-up.
    Carcas-Sansuán AJ; Espinosa-Román L; Almeida-Paulo GN; Alonso-Melgar A; García-Meseguer C; Fernández-Camblor C; Medrano N; Ramirez E
    Pediatr Nephrol; 2014 Jan; 29(1):117-23. PubMed ID: 23907143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial.
    Bakr MA; Nagib AM; Donia AF; Denewar AA; Abu-Elmagd MM; Abbas MH; Abdel-Rahman AM; Mashaly ME; Elsaftawy MM; Ghoneim MA
    Saudi J Kidney Dis Transpl; 2018; 29(6):1267-1273. PubMed ID: 30588956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once- versus twice-daily tacrolimus: are the formulations truly equivalent?
    Barraclough KA; Isbel NM; Johnson DW; Campbell SB; Staatz CE
    Drugs; 2011 Aug; 71(12):1561-77. PubMed ID: 21861541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
    Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified release tacrolimus in de novo immunosuppression after simultaneous pancreas-kidney transplantation--a first single-center experience.
    Schenker P; Klein T; Krüger B; Claas S; Wunsch A; Traska T; Krämer BK; Viebahn R
    Transplant Proc; 2009; 41(6):2573-5. PubMed ID: 19715977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous pancreas-kidney transplantation in the mycophenolate mofetil/tacrolimus era: evolution from induction therapy with bladder drainage to noninduction therapy with enteric drainage.
    Kaufman DB; Leventhal JR; Koffron A; Gheorghiade M; Elliott MD; Parker MA; Abecassis MM; Fryer JP; Stuart FP
    Surgery; 2000 Oct; 128(4):726-37. PubMed ID: 11015108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.
    Arns W; Huppertz A; Rath T; Ziefle S; Rump LC; Hansen A; Budde K; Lehner LJ; Shipkova M; Baeumer D; Kroeger I; Sieder C; Klein T; Schenker P
    Transplantation; 2017 Nov; 101(11):2780-2788. PubMed ID: 28658202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.